SEMEY STATE MEDICAL UNIVERSITY

Prepared by: Zhumakanova T.M

Course : 3

Faculty: Stomatology

Checked by:

Semey 2017



Meningococcal Disease: Overview of a Rare but Potentially Deadly Infection

Meningococcal Disease in the United States

- A bacterial infection
 - Neisseria meningitidis
- An unpredictable disease



Getty Images/ROYALTYSTOCKPHOTO

- 98% of cases are sporadic; fewer than 2% are related to outbreaks¹
- Typically occurs among previously healthy children and adolescents²
- Approximately 2100-3400 cases occurred annually in the 1990s³
 - Approximately 370-1000 per year during 2009-2015^{4,5}



Outcomes Can Be Severe, Even with Treatment

- Serious outcomes include meningitis (most common clinical presentation) and meningococcemia (bloodstream infection)¹
- Death rate of 10%-15%, even with antibiotic therapy¹
 - Death rate even higher (up to 40%) for patients who develop meningococcemia¹
- Up to 20% of people who survive meningococcal disease suffer lifelong disability²
 - Amputation of arms or legs, hearing loss, brain damage



Courtesy of National Meningitis Association



Time Is of the Essence

- Early symptoms are nonspecific
 - Fever, headache, nausea, vomiting, loss of appetite
 - Mimic symptoms of common viral illnesses
- Characteristic symptoms occur later
 - Hemorrhagic rash, neck stiffness, photophobia
 - Typically develop approximately 12-15 hours after symptoms begin¹
- Rapid progression



Death may occur within 24 hours of symptom onset^{1,2}



Modes of Transmission Help Explain Vulnerability of Adolescents and Young Adults

- Spread through respiratory and throat secretions¹
 - Coughing, sneezing
 - Kissing
 - Sharing eating utensils, water bottles, etc
- Crowded settings facilitate transmission
 - College dormitory²
 - Crowded household²
 - Military barracks
 - Nightclubs, bars



Getty Images/Nick Daly



Helping to Protect Through Timely and Complete Immunization: 2 Doses of MCV4

Meningococcal Vaccines in the US Recommended for Use in Adolescents and Young Adults

	Quadrivalent meningococcal conjugate (MCV4)	Meningococcal B (MenB)
Year first licensed	2005	2014
Serogroup(s)	A, C, W, Y	В
Recommendations	Recommended for routine use in adolescents	Recommended, based on individual clinical decision making, for adolescents and young adults 16–23 years of age



ACIP Recommendations for Routine MCV4 Vaccination¹

- First dose of MCV4 at **11** or **12** years of age
 - Recommended since 2005 by CDC's Advisory Committee on Immunization Practices (ACIP)
- A second dose at 16 years of age
 - Recommended since 2010 by ACIP



Courtesy of CDC/James Gathany



Putting the Numbers Together

Estimated US population of adolescents 13–17 years of age in 2015: 21 million¹ Pool of potentially unprotected adolescents (no MCV4 primary dose): 3.9 million

Estimated US population of 17-year-olds in 2015: 4.2 million¹ Pool of potentially under-protected 17-year-olds (no MCV4 booster dose): 2.8 million





Call to Action: What You Can Do to Help Protect Adolescents

Strongly Recommend Meningococcal Immunization

- A health care provider's recommendation to vaccinate is a powerful motivator for patients to get immunized¹
- Reinforce your recommendation with an environment that is:
 - Enthusiastically pro-vaccine
 - Committed to fully vaccinating ALL eligible adolescent patients, regardless of whether they are college bound
- Provide training, promote leadership
 - Educate staff on meningococcal disease
 - Keep them up-to-date on all ACIP vaccine recommendations
 - Make sure they are fully immunized themselves with the vaccinations they need
 - Consider designating a vaccine champion or team of champions



Focus on Key Points When Speaking with Patients

- Meningococcal disease is rare but potentially deadly for people your age
- You are at increased risk from your mid-to-late teens into your early 20s
- Disease can come on suddenly, without warning, and can quickly become life-threatening
- The disease can result in severe, lifelong disability, such as hearing loss, amputation of arms or legs, and brain damage
- Meningococcal vaccine is safe and effective
- For routine vaccination, 2 doses are recommended





- Follow ACIP recommendations for routine MCV4 immunization¹
 - Give dose 1 at 11-12 years of age AND dose 2 at 16 years of age
 - Use every opportunity to provide the booster dose when indicated



Vaccinate! (cont.)

Follow ACIP guidance if dosing is delayed¹:

- If dose 1 is given at 13-15 years of age, administer dose 2 at 16-18 years of age
 - Observe minimum interval of 8 weeks between doses
- − If dose 1 is given at \geq 16 years of age,^a dose 2 is not needed

^a A catch-up dose may be administered through 21 years of age to those who have not received a dose after their 16th birthday (eg, first-year college students 19-21 years of age living in residence halls)



Capture Every Opportunity to Immunize

- Consider every patient encounter an opportunity to vaccinate with MCV4 and all other age-appropriate vaccines¹⁻³
 - Well visits
 - Acute care and follow-up visits
 - Sports and camp physicals
 - Routine visits for chronic illnesses (eg, asthma)
 - Visits for influenza vaccines



Administer all indicated vaccines at the same visit^{2,3}



Implement Immunization Processes and Procedures

- Check immunization status of patients at every visit ("vital sign")
 - Review immunization information system (IIS) record
- Establish mechanisms to identify patients due for vaccination
 - Electronic medical record (EMR) prompts
 - "Immunization due" clip attached to paper chart
- Screen for contraindications and precautions
 - Screening checklist:
 www.give2mcv4.org/essential-tools/screening-checklist-contraindicatio
 ns-teen-vaccines

DOSES to Strengthen Protection

 Develop protocols for vaccinating minors who present for care without a parent^{1,2}

17

Tool Up

- Standing orders
- Patient reminder and recall systems
 - Strong evidence of effectiveness in improving adolescent vaccina
 - Checklists, standing orders, tip sheets, patient handouts, and more



Measure Up

- Measure your practice's vaccination rates at least annually^{1,2}
 - IIS
 - EMR system
 - Chart audit
 - Claims data review
 - Assessment, Feedback, Incentives, and eXchange (AFIX)





Strengthen the Partnership

- Recognize that success at immunization is a partnership between the health care provider, the adolescent, and the family
- Share your practice's pro-immunization philosophy and policies with every patient and family from the time of their first visit
 - Develop a written vaccination policy you can share with families
- Make vaccine education visible, accessible, and plentiful
 - Brochures, Vaccine Information Statements, posters, handouts for parents and teens, and website referrals
 - Designated staff members ready to provide vaccine information and answer questions



Take Action!

- Identify adolescents in your practice who are eligible for their second dose of meningococcal vaccine
- Establish a goal for immunizing these patients



 Develop and commit office resources toward achieving that goal

Remember, you're not done if you give just one.

